



Press release

Stockholm, 12 June 2015

CEO Niels Christiansen leaves Bactiguard

Niels Christiansen leaves his position as CEO of Bactiguard Holding AB (publ) with immediate effect. The Board has appointed Christian Kinch, currently Chairman of the Board, as new CEO. Stanley Brodén has been appointed Chairman of the Board until the Annual General Meeting (AGM) in 2016.

“The recruitment of Niels Christiansen as CEO was unfortunately not right for Bactiguard and therefore he leaves the company. The Board has appointed me as the new CEO and thereby secured continuity in the company. At the same time, the Board has appointed Stanley Brodén as Chairman, to split the roles as Chairman and CEO,” says Christian Kinch.

Niels Christiansen assumed his position as CEO in Bactiguard in March 2015. Christian Kinch has been the Chairman of the Board since 2014 and between 2005 and March 2014 he was CEO of the company. Stanley Brodén previously served as CEO of Aleris and was elected Board member of Bactiguard at the AGM in 2015.

This is information that Bactiguard Holding AB (publ) is required to publish in compliance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on 12 June 2015, at 13.45

For further information, please contact:

Cecilia Edström, Acting Director of Sales, Marketing & Communications,
mobile: +46 722 262 328, email: cecilia.edstrom@bactiguard.com

About Bactiguard

Bactiguard is a Swedish medtech company with a mission of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company's patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the Europe, Middle East, Asia, Latin America and Southern Africa. The company has market presence in some 50 countries and has about 60 employees. Its headquarters are located in Stockholm and production facilities in Sweden and Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com.